A significant legal development emerged in late March that raises the stakes of 340B compliance: the Ninth Circuit Court of Appeals ruled that False Claims Act (FCA) claims may proceed based on alleged violations tied to the 340B statute in Adventist Health System Southwest v. AbbVie.
Historically, 340B compliance issues have been addressed through administrative mechanisms such as audits, repayment, or program sanctions. This decision signals that, in certain circumstances, alleged noncompliance could also be evaluated under federal fraud frameworks.
While the ruling is limited to the Ninth Circuit, it may influence how similar cases are argued and evaluated in other jurisdictions.
What the Ruling Actually Means
The False Claims Act is the federal government’s primary anti-fraud statute, carrying civil penalties of $13,000 to $26,000 per claim, plus treble damages.
The Ninth Circuit’s decision allows a case to move forward under the theory that if a covered entity certifies compliance with 340B requirements in connection with a federal healthcare claim, and that certification is materially false, FCA liability could apply. This does not mean every 340B compliance issue automatically triggers FCA exposure. However, it introduces a new layer of risk.
A More Scrutinized Environment Is Already Taking Shape
This ruling does not exist in isolation. It comes amid:
- A CMS drug acquisition cost survey focused on 340B pricing
- An active Health Resources and Services Administration (HRSA) Request for Information on the 340B rebate model
- Increased federal focus on program integrity and fraud enforcement
The direction is clear: documentation and defensibility of 340B operations are critical.
Duplicate Discounts Remain the Most Common Risk Area
One of the most frequent 340B compliance challenges is duplicate discounts: when a covered entity accesses 340B pricing while Medicaid also claims a rebate on the same drug.
These situations are often unintentional and stem from gaps in carve-in/carve-out strategies or patient-level tracking. However, repeated or poorly controlled occurrences, especially those without clear documentation, can increase exposure in a more enforcement-focused environment.
Where PIAP Strengthens Both Compliance and Stability
A well-structured Premium Insurance Assistance Program (PIAP) introduces a more defined and auditable patient coverage pathway. Patients enrolled in PIAP are covered by commercial insurance plans rather than Medicaid for those services. As a result:
- Claims are processed through commercial payers
- Medicaid rebate interactions are avoided for those encounters
- Duplicate discount risk is structurally reduced for that population
In this way, PIAP supports not only access and continuity of care, but also a more clearly documented and segmented reimbursement model.
In a tightening regulatory environment, documentation and structure matter more than ever. Contact American Exchange to explore how PIAP can support both compliance and long-term program stability.
Sources
Ninth Circuit Allows FCA Claims Based on 340B Violations – Davis Wright Tremaine
